Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis

Autor: Ken Kusama, Yoshimasa Kubota, Teizo Murata, Kazumichi Kawakubo, Naoya Sakamoto, Yuka Kobayashi, Yoichi M. Ito, Shinji Togo, Takaaki Ikeda, Hiroshi Kawakami, Masaki Kuwatani
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
endocrine system diseases
Endocrinology
Diabetes and Metabolism
Gastroenterology
Fucose
chemistry.chemical_compound
0302 clinical medicine
CEA
Fucosylated haptoglobin
Medicine
Aged
80 and over
biology
Haptoglobin
Middle Aged
CA19-9
030220 oncology & carcinogenesis
Area Under Curve
030211 gastroenterology & hepatology
Female
Adult
medicine.medical_specialty
CA-19-9 Antigen
Sensitivity and Specificity
03 medical and health sciences
Pholiota squarrosa
Internal medicine
Pancreatic cancer
Pancreatitis
Chronic
Biomarkers
Tumor
Humans
False Positive Reactions
Aged
Hepatology
Intraductal papillary mucinous neoplasm
Haptoglobins
business.industry
Lectin
Pancreatic Diseases
Reproducibility of Results
medicine.disease
biology.organism_classification
digestive system diseases
Carcinoembryonic Antigen
Pancreatic Neoplasms
chemistry
biology.protein
Pancreatitis
business
Zdroj: Pancreatology. 19(4):569-577
ISSN: 1424-3903
Popis: Background: Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL) that had specificity for fucose alpha 1-6 was reported as an effective biomarker for several gastrointestinal diseases. The aim of this study was to verify Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL-HP) as a pancreatic cancer (PC) marker using a new method of PhoSL-ELISA. Methods: PhoSL-HP in sera from 98 PC patients and 158 non-PC samples including 32 intraductal papillary mucinous neoplasm (IPMN) patients, 21 chronic pancreatitis (CP) patients and 105 non-pancreatic disease controls (NPDC) were measured. We compared sensitivities, specificities and areas under the curves (AUC) of PhoSL-HP, CA19-9 and CEA as single markers. We also evaluated PhoSL-HP as combination marker by comparing AUC of CA19-9 combined with PhoSL-HP or CEA. Results: The sensitivities of PhoSL-HP, CA19-9 and CEA for PC were 58%, 76% and 42%, respectively. Although the specificity of PhoSL-HP for NPDC was inferior to both of CA19-9 and CEA, that for pancreatic diseases was higher than both of CA19-9 and CEA. Combined CA19-9 with PhoSL-HP, the AUC was significantly higher at 0.880 than single use of CA19-9 at 0.825 in case of distinguishing PC from other pancreatic diseases. In contrast, the AUC of CA19-9 was not elevated significantly when combined with CEA. Conclusion: PhoSL-HP would be a useful marker for PC and have sufficient complementarity for CA19-9. (C) 2019 Published by Elsevier B.V. on behalf of IAP and EPC.
Databáze: OpenAIRE
Externí odkaz: